X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ORCHID PHARMA LTD - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD ORCHID PHARMA LTD LUPIN LTD/
ORCHID PHARMA LTD
 
P/E (TTM) x 16.8 -0.6 - View Chart
P/BV x 3.9 0.5 858.8% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 LUPIN LTD   ORCHID PHARMA LTD
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
ORCHID PHARMA LTD
Sep-13
LUPIN LTD/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs2,127194 1,096.4%   
Low Rs1,29435 3,697.4%   
Sales per share (Unadj.) Rs304.1276.5 110.0%  
Earnings per share (Unadj.) Rs50.4-79.2 -63.6%  
Cash flow per share (Unadj.) Rs60.7-43.5 -139.7%  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs243.853.9 452.0%  
Shares outstanding (eoy) m450.5870.45 639.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.60.4 1,358.2%   
Avg P/E ratio x33.9-1.4 -2,348.1%  
P/CF ratio (eoy) x28.2-2.6 -1,069.7%  
Price / Book Value ratio x7.02.1 330.5%  
Dividend payout %14.90-   
Avg Mkt Cap Rs m770,7408,067 9,554.8%   
No. of employees `00016.42.8 584.0%   
Total wages/salary Rs m21,0772,527 834.1%   
Avg. sales/employee Rs Th8,379.66,956.1 120.5%   
Avg. wages/employee Rs Th1,289.0902.5 142.8%   
Avg. net profit/employee Rs Th1,388.7-1,993.0 -69.7%   
INCOME DATA
Net Sales Rs m137,01619,477 703.5%  
Other income Rs m1,877407 461.0%   
Total revenues Rs m138,89319,884 698.5%   
Gross profit Rs m37,5351,103 3,404.2%  
Depreciation Rs m4,6352,519 184.0%   
Interest Rs m4465,227 8.5%   
Profit before tax Rs m34,330-6,236 -550.5%   
Minority Interest Rs m-8820 -444.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m11,536-125 -9,213.9%   
Profit after tax Rs m22,707-5,580 -406.9%  
Gross profit margin %27.45.7 483.9%  
Effective tax rate %33.62.0 1,673.7%   
Net profit margin %16.6-28.7 -57.8%  
BALANCE SHEET DATA
Current assets Rs m97,79011,014 887.9%   
Current liabilities Rs m53,87232,060 168.0%   
Net working cap to sales %32.1-108.1 -29.7%  
Current ratio x1.80.3 528.4%  
Inventory Days Days8595 89.3%  
Debtors Days Days12134 361.2%  
Net fixed assets Rs m86,37929,440 293.4%   
Share capital Rs m901705 127.9%   
"Free" reserves Rs m105,7352,043 5,176.5%   
Net worth Rs m109,8443,800 2,890.7%   
Long term debt Rs m53,7399,018 595.9%   
Total assets Rs m224,37846,510 482.4%  
Interest coverage x77.9-0.2 -40,357.9%   
Debt to equity ratio x0.52.4 20.6%  
Sales to assets ratio x0.60.4 145.8%   
Return on assets %10.3-0.8 -1,357.7%  
Return on equity %20.7-146.9 -14.1%  
Return on capital %21.2-3.7 -567.8%  
Exports to sales %49.137.9 129.6%   
Imports to sales %7.422.6 32.9%   
Exports (fob) Rs m67,2447,378 911.5%   
Imports (cif) Rs m10,1994,406 231.5%   
Fx inflow Rs m71,4057,513 950.4%   
Fx outflow Rs m17,8075,649 315.2%   
Net fx Rs m53,5981,865 2,874.6%   
CASH FLOW
From Operations Rs m-3,6901,682 -219.4%  
From Investments Rs m-69,434-9,860 704.2%  
From Financial Activity Rs m58,1266,644 874.9%  
Net Cashflow Rs m-14,998-1,535 977.1%  

Share Holding

Indian Promoters % 46.6 32.3 144.3%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 4.6 245.7%  
FIIs % 31.9 3.3 966.7%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.1 55.3 18.3%  
Shareholders   98,259 84,811 115.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  MERCK LTD  BIOCON LTD  J.B.CHEMICALS  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 23, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - DISHMAN PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS